The examination of human Individual differences at all levels of biological and phenotyplc analysis will provide Important Insights Into the mechanisms underlying complex traits. In particular, Individual differences In response to addictive substances may help to elucidate the medianlsms underlying drug action, addiction, reward, and reward related disease states. "The individual" has, both conceptually and concretely, been banned for far too long from approaches to scientific investigation. At the heart of endeavours to describe the functions and dysfunctions of "the" organism was the determination of mean values, as the averages of all individual values, and a standard error that indicated the extent of deviation of the individual values from the "mean," or "true" value. In other words, individual variation was conceived exclusively as the result of errors introduced in the process of measurement. At its extreme, the mean value would describe an effect that did not apply to any of the individuals studied. In this paradigm, the approach to gaining insight into the mechanisms underlying disease was based on the comparison of mean values between patients and healthy controls, usually resulting from a one-off experiment. Thus, in order to test an involvement of the opioidergic system in depressive disorders, we compared neuroendocrine and behavioral responses to the highly potent µ opiate receptor agonist fentanyl, both in patients and controls. At the time, insights Into central receptor functions In humans were to be gained only Indirectly: pharmacological substances known to Inter act with central nervous system receptors were administered intravenously, and receptor-mediated effects such as the release of hormones were measured peripherally as indicators of receptor function.

Evidence for individual variation in response to µ opiate receptor agonist administration
=========================================================================================

In order to prepare the ground for such an opiate challenge in patients, we had performed, first, a systematic dose-response study in normal volunteers. Doses of 0.1, 0.2, and 0.25 mg fentanyl per 70 kg body weight were tested in a randomized design at 3-week intervals, and specific dose-related effects on the release of prolactin, growth hormone, Cortisol, catecholamines, and euphoric responses were able to be demonstrated. In particular, this work presented the first experimental evidence of a dose-dependent increase in the rewarding properties of fentanyl. A dose of 0.2 mg per 70 kg body weight proved suitable to reliably induce an opiatespecific effect without causing adverse side effects or stress reactions.^[@ref1]-[@ref4]^ When this dose was administered to depressive patients in a one-off experiment, both mean growth hormone and euphoric response to fentanyl was significantly reduced compared with normal controls.^[@ref5]^ This suggested a possible involvement of µ opioid receptor-related function in depression.

Most interestingly, when the individual responses underlying the mean euphoric effect of fentanyl in normal volunteers *([Figure 1](#DialoguesClinNeurosci-9-471-g001){ref-type="fig"}A)* were examined, a remarkable individual variation was observed *([Figure 1](#DialoguesClinNeurosci-9-471-g001){ref-type="fig"}B),* One fourth of the "normal" volunteers did not exhibit any euphoric reaction, or showed a decrease in well-being. Evaluation of euphoric responses was based on: (1) application of visual analogue scales; (ii) documentation and classification of all spontaneous verbal reports of the volunteers; and (iii) detailed documentation of all observations during the experiment by two experts. These different instruments were found to be highly concordant, allowing unambiguous classification of the volunteers\' behavioral patterns. Moreover, these individual response patterns proved consistently evocable over time, ie, in the course of repeated applications of fentanyl.^[@ref2],[@ref6]^ This suggested that individual responsiveness to this µ opiate receptor agonist might represent a trait variable, and that "normal" individuals might be classified into drug responders and nonresponders *([Figure 1](#DialoguesClinNeurosci-9-471-g001){ref-type="fig"}C).^[@ref2]^* Similar observations were made upon administration of morphine.^[@ref2]^ This suggests that a subgroup of individuals may not be disposed to experience euphoria upon exposure to addictive drugs. Absence of euphoric response was not correlated with a blunted growth hormone release upon application of fentanyl or morphine, suggesting that different (opioid) mechanisms might be involved in mediation of rewarding properties of addictive substances. Thus, tracking a potential genetic basis underlying nonresponse may provide important clues the mechanisms involved in the development of addiction, or in a more general way the personal disposition to experience reward, and potentially lead to targets of intervention.

![Euphoric responses to µ opiate receptor agonist administration. A) Visual analogue scale (VAS) scores as mean values before and up to 60 min after administration of 0.2 mg fentanyl/kg; 0 mm = very unpleasant feelings; 1 00 mm = extremely positive feelings. B) Visual analogue scale scores presented as individual values before and up to 60 min after administration of 0.2 mg fentanyl/kg. C) Classification of individual VAS scores into two response types, euphoric responders / nonresponders.](DialoguesClinNeurosci-9-471-g001){#DialoguesClinNeurosci-9-471-g001}

Evidence for abundant DNA sequence variability in the gene encoding the human µ opiate receptor
===============================================================================================

Major advances in human molecular genetics in the late 1980s led to the cloning of numerous genes encoding pharmacologically characterized receptors. This allowed in principle to address the role of receptors in disease and individually different drug response for the first time at the most basic level, that is, DNA sequence information. If DNA sequence differences in the receptor gene were identified that were correlated with the individual phenotype in question, this could provide important clues on underlying receptor dysfunction and its nature. Since it is the entire gene and its encoded protein that act as the units of function which potentially affect a phenotype (and ultimately allow the first conclusions on disease mechanisms), it appeared mandatory to analyze the entire sequences of the individual genes, including their regulatory and critical intronic sequences. This required DNA sequence analyses at a previously unprecedented scale, in the Megabase range. Thus, we developed a powerful technique to perform comparative candidate gene sequencing in large numbers of patients and controls, "Multiplex Polymerase Chain Reaction (PCR) Sequencing." In principle, this technology allowed processing multiple (up to 55) sequencing reactions simultaneously in one reaction tube, increasing throughput accordingly. As a second prerequisite, we generated significant information on the genomic organization of the human µ opiate receptor gene, extending the previously cloned complimentary DNA (cDNA) sequence information^[@ref7]^ significantly. We determined several kb of 5\' regulatory region, identified a number of potential binding sites for transcriptional regulatory factors, and cloned critical intronic sequences.^[@ref8]^

These lines of research and technology development were combined to conduct the first systematic and to date most comprehensive analysis of DNA sequence variation in the human µ opiate receptor gene (OPRMf ).^[@ref9]^ In a total of 250 individuals with a phenotype of severe substance (heroine/cocaine dependence and controls from two major populations, AfricanAmericans and European-Americans, abundant DNA sequence diversity was revealed *([Figure 2](#DialoguesClinNeurosci-9-471-g002){ref-type="fig"}).* Regarding the nature and distribution of sequence variation in OPRM1, a total of 43 biallelic variants were identified. Clearly, the density of variants was higher in the 5\' regulatory and untranslated regions than in the coding regions, where six variants, five of which affect the encoded protein, were found. Functional analyses of several of these mutations in the coding were performed, characterizing in particular modification of receptor density and signaling *([Figure 3](#DialoguesClinNeurosci-9-471-g003){ref-type="fig"}).* ^[@ref10]^ Moreover, the influence of allelic variation in the 5\' region on regulation of OPRMf transcription was analyzed in a first study.^[@ref11]^

![Polymorphic spectrum of the 0PRM1 gene. The 6968 bp genomic reference sequence is presented as baseline; base pair coordinates relative to the translation start site are given. Sequences are drawn to scale, which is indicated. All gene variants are specified by position numbers and nucleotide variations (substitutions, insertions and deletions) according to mutation nomenclature. Those sites marked by an asterisk have been included in the haplotype analysis. Reproduced from ref 9: Hoehe MR, Köpke K, Wendel B, Flachmeier C, Kidd KK, Berrettini WH, Church GM. Sequence variability and candidate gene analysis in complex disease: association of I opioid receptor gene variation with substance dependence. *Hum Mol Genet.* 2000;19:2895-2908. Copyright © IRL Press at Oxford University Press 2000](DialoguesClinNeurosci-9-471-g002){#DialoguesClinNeurosci-9-471-g002}

![Site-directed mutagenesis of amino acid residues of OPRM1. A schematic representation of the putative seven transmembrane domain topology of the receptor is shown. Polymorphisms that affect protein sequence are indicated, and the mutations examined highlighted. Reproduced from ref 10: Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL. A single nucleotide polymorphic mutation in the human u-opioid receptor severely impairs receptor signaling. *J Biol Chem.* 2001;276:3130-3137. Copyright © American Society for Biochemistry and Molecular Biology 2001](DialoguesClinNeurosci-9-471-g003){#DialoguesClinNeurosci-9-471-g003}

Multiple individually different forms of the human µ opiate receptor gene: relationship to gene function and phenotype
======================================================================================================================

The given sequence variability gives rise to numerous individually different forms of the OPRM1 gene. It is essential In diploid organisms to determine the specific combinations of given gene sequence variants for each of the chromosomes defined as haplotypes. Because current experimental methods to determine the molecular haplotypes are still too labor- and cost-Intensive, statistical techniques were applied at this stage to predict these. In the group of African- American substance-dependent Individuals and controls, a total of 52 different haplotypes were distinguished *([Figure 4](#DialoguesClinNeurosci-9-471-g004){ref-type="fig"}A).^[@ref9],[@ref12]^* These occurred at different frequencies in the population, as illustrated In *[Figure 4](#DialoguesClinNeurosci-9-471-g004){ref-type="fig"}B.* The five most frequent haplotypes, nos 43, 14, 4, 24, and 7 were common to both substance-dependent Individuals and controls and constituted 66% to 73% of all haplotypes. An additional four of less frequent haplotypes were predicted, and a large number (43) of rare haplotypes occurring at frequencies \<1% amounted to a total of 20% of all haplotypes. Thus, we will have to abandon Mendel\'s two-allele concept of a gene, which implicated existence of both a predominant "wild type" and various mutant forms.

![The human p opiate receptor study. A. The multiplicity of haplotypes. The polymorphic sites are specified by positions 1-25, marked by an asterisk in *Figure* 2; 1, identical with the reference sequence; *2,* different from the reference sequence. B. Distribution of haplotypes. Haplotype frequencies are given in percentages, different haplotypes are color-coded and correspond to the haplotypes marked in A. Reproduced in part from ref 1 2: Hoehe MR. Haplotypes and the systematic analysis of genetic variation in genes and genomes. *Pharmacogenomics.* 2003;4:547-570. Copyright © Future Medicine Ltd 2003](DialoguesClinNeurosci-9-471-g004){#DialoguesClinNeurosci-9-471-g004}

The picture exemplified at the model of OPRM1 apparently applies, In view of our more extended candidate gene analyses, to at least one third of all genes studied.^[@ref13]^ Allelic complexity In candidate genes may be large, and pose particular challenges to the analysis of genotype-phenotype relationships, particularly In the situation of complex traits. At first sight, such multiplicity of gene forms seems Irreconcilable with the assumption of dichotomous traits such as health and disease, or drug response and nonresponse. Moreover, the number of different haplotypes Is unfeaslbly large, so that the power Is not sufficient to detect an

association with any single haplotype. This will require novel approaches to cope with the multiplicity of haplotypes. An appropriate approach seems the classification of haplotypes Into functionally related (Ideally functionally equivalent) ones based on sequence-structure-function similarity Once a classification has been derived, the haplotype frequencies of cases and controls In the different classes can be compared. By this approach, the multiplicity of haplotypes could be condensed to two functionally related categories, one of which was more frequent In substance-dependent Individuals.^[@ref9]^ Common to this category was a characteristic pattern of sequence variants located In the 5\' regulatory region, reflecting a specific constellation of putative transcription regulatory motifs that may confer different regulatory properties.^[@ref9],[@ref12]^ Taken together, this analysis at the gene level demonstrates a remarkable gene sequence and haplotype diversity, the rule rather than the exception for the majority of candidate genes. This work provides, moreover, an example of approaches that can be successfully applied to establish complex genotype-phenotype relationships against a background of high natural genome sequence diversity

Perspectives
============

Observed diversity presents challenges to the traditional views of the concept of "a" gene with far-reaching implications on the analysis of "gene" "function" relation-ships.^[@ref13],[@ref14]^ Classical single mutation analysis no longer appears appropriate. The units of functional analysis must be the entire individual sequence of haplotypes, involving potentially abundant variation in *all* regulatory, coding, and intronic sequences. Analysis will include the spectrum of haplotypes existing in a population, and the pairs of haplotypes existing in each individual We have now determined in a first comprehensive study the molecular haplotypes of a key candidate gene in hundreds of individuals, confirming the existence of multiple individually different forms of a gene at the molecular level (Hoehe et al, in preparation). This work provides at the same time knowledge of the concrete molecular templates to allow dissection of what may be an entire spectrum of functions underlying molecular gene diversity.

At this stage, individual variation and its functional implications have been addressed at the level of a single gene only However, this is integral part of an entire network of genes as a higher-level functional unit; multiple individual molecular haplotypes interact to produce a common output signal Thus, progress in the future is expected to come from whole systems analysis-based approaches,^[@ref13]^ integrating individual variation in all genes involved in all pathways of relevance. This will prepare the basis for "personalized" medicine in its true sense.
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